Clinical Trial Update: Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial evaluating eyeDNA Therapeutics’ PDE6B gene therapy for retinitis pigmentosa caused by PDE6B mutations has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• eyeDNA PDE6B gene therapy

Snippet

Sponsor: eyeDNA Therapeutics | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: TERMINATED